Can Mono Flare Up Again? Reactivation and Symptoms

Mono can reactivate because the virus that causes it, Epstein-Barr virus (EBV), never actually leaves your body. After the initial illness resolves, EBV settles into a small population of immune cells and stays there for life, held in check by your immune system. When that immune control weakens, the virus can wake up and start replicating again. Whether that reactivation produces noticeable symptoms, and what those symptoms look like, depends on several factors that make this a more layered question than it first appears.

Why the Virus Never Goes Away

EBV has evolved a remarkably effective survival strategy. After the acute phase of mono, the virus retreats into memory B cells, a type of long-lived immune cell that normally sticks around for decades to remember past infections. Research has confirmed that EBV-infected cells in the bloodstream display all the molecular hallmarks of normal, antigen-selected memory B cells, meaning the virus essentially disguises itself inside cells that your body is designed to keep alive indefinitely.¹ In this dormant state, the virus produces very few proteins and mostly stays invisible to immune surveillance. It is a lifelong arrangement: roughly 95% of the world’s adult population carries EBV, and most never know the virus is still there.

Your immune system, particularly specialized T cells, acts as a constant watchdog. These cells patrol for signs that EBV-infected cells are becoming active and destroy them when they do.² Even with a healthy immune response, EBV periodically switches on in some cells. In most people, this low-level activity produces no symptoms at all. One study found EBV DNA in the throat washings of 90% of healthy adults, evidence that the virus regularly reactivates enough to be shed in saliva even when a person feels perfectly fine.³

What Triggers Reactivation

The immune system’s grip on EBV is not always equally tight. Several situations can loosen that grip enough for the virus to start replicating more aggressively.

Psychological and physical stress is the trigger people ask about most often. Studies have documented that periods of high stress, such as exam weeks for students, are associated with elevated antibody titers against EBV, a serological sign that the virus has become more active. One study found these antibody changes occurred even when cortisol levels did not rise significantly, suggesting that stress hormones are not the only pathway involved and that other signaling molecules play a role.⁴ A separate study measuring stress hormone levels directly found that subjects with elevated cortisol and epinephrine had significantly higher rates of EBV reactivation.⁵ The picture is that stress reliably wakes the virus up, but the precise hormonal pathway varies from person to person.

At the cellular level, researchers have recently identified that a specific inflammatory molecule, interleukin-17 (IL-17), can directly flip the switch on EBV latency. Lab experiments showed that IL-17 alone was sufficient to activate the virus’s lytic replication program, prompting infected cells to start producing new virus particles.⁶ IL-17 is produced during many inflammatory conditions, which helps explain why other illnesses can provoke EBV reactivation as a secondary event.

Severe illness is another well-documented trigger. Among patients hospitalized with COVID-19, about 27% showed signs of EBV reactivation, roughly double the rate seen in a control group without COVID.⁷ Critically ill ICU patients show similar patterns regardless of the underlying illness, with EBV reactivation identified in about 16% of severe COVID-19 patients and 14% of non-COVID ICU patients in one large case series.⁸ The takeaway is that any condition placing your body under intense physiological stress can create the conditions for EBV to reactivate.

What Reactivation Symptoms Look Like

This is where expectations and reality often diverge. Most people who had a miserable bout of mono as a teenager imagine reactivation as a full-blown repeat of that experience. It rarely works that way. The classic triad of mono, fever, sore throat, and swollen lymph nodes, is most common during a first infection in young people.⁹ Reactivation, by contrast, tends to present differently.

A study comparing primary EBV infection and reactivation in children found that while primary infection overwhelmingly presented as classic infectious mononucleosis (about 99.8% of cases), only 65% of reactivation cases looked like mono. The rest appeared as more serious conditions including hemophagocytic syndrome (about 23%), chronic active EBV infection (about 5%), and lymphoma (about 4%).¹⁰ Symptoms that were hallmarks of the first infection, such as swollen tonsils, periorbital swelling, and enlarged liver, appeared at much lower rates during reactivation. Patients with reactivation were also more prone to complications affecting multiple organ systems.

In adults, the picture shifts again. The typical young-adult experience of fever and sore throat becomes less representative with age, and abnormal liver function tests become a more prominent finding.¹¹ Many adults experiencing reactivation describe weeks of unexplained fatigue, mild body aches, or a general feeling of being unwell, without the dramatic throat pain and lymph node swelling they remember from their first infection. This subtler presentation often leads people to attribute their symptoms to overwork or a lingering cold rather than a viral reactivation.

When Reactivation Becomes Dangerous

For people whose immune systems are compromised, whether by medications, organ transplants, HIV, or other conditions, EBV reactivation carries genuinely serious risks. One study found that immunocompromised patients with chronic skin diseases showed a 6.7% rate of subclinical EBV reactivation compared to 0% in patients whose immune systems were intact, and EBV DNA was detectable in skin tissue in about 31% of immunocompromised patients versus none in the control group.¹² For these patients, what would be a silent viral blip in a healthy person can become a clinically meaningful problem.

The most extreme form of this is chronic active EBV disease (CAEBV), a rare condition where the body completely loses control of the virus. People with CAEBV have persistently elevated levels of EBV in their blood and can develop fever, enlarged spleen, hepatitis, and dangerously low blood counts.¹³ Without treatment, the disease progresses toward life-threatening complications including organ failure and EBV-driven cancers.¹⁴ Diagnosis is frequently delayed because the symptoms overlap with so many other conditions. A study of 149 pediatric CAEBV patients found a median diagnostic delay of six months, with over 40% initially presenting with atypical, localized symptoms rather than the systemic illness clinicians expect.¹⁵ CAEBV is worth knowing about not because it is common, but because early recognition dramatically improves outcomes.

Figuring Out Whether EBV Is Behind Your Symptoms

Diagnosing EBV reactivation is trickier than diagnosing a first-time mono infection. The standard blood tests that work well for an initial infection can produce confusing results when reactivation is the question. In a straightforward first infection, you would expect to see certain antibody patterns: positive VCA IgM (a marker of recent infection) and positive VCA IgG, but no EBNA-1 IgG (which develops later). Past infection shows VCA IgG and EBNA-1 IgG without VCA IgM. Reactivation muddies this, sometimes producing all three markers at once.¹⁶

When initial blood tests are ambiguous, additional testing steps can help clarify the picture. These include measuring the maturity of EBV-specific antibodies (a technique called avidity testing), looking for antibodies against a protein called early antigen, or directly measuring viral DNA levels in the blood. One evaluation of EBV diagnostic approaches across multiple testing platforms found concordant results only 71% of the time, with most disagreements arising from the early antigen test.¹⁷ The practical upshot for you: if you suspect EBV reactivation, expect that your doctor may need to order more than a basic mono test, and be prepared for the possibility that results require interpretation rather than a clear yes-or-no answer.

Another complicating factor is that mono-like symptoms are not always caused by EBV alone. A study of children with suspected mono found that co-infection with other pathogens was common, occurring in roughly 63% to 81% of patients depending on whether EBV, cytomegalovirus, or both were involved.¹⁸ Multiple infections circulating at the same time can amplify symptoms and make it harder to pin the blame on any single virus.

The EBV-Fatigue Connection

A question that lingers for many people after mono is whether the virus might be responsible for persistent fatigue that never fully resolves. The relationship between EBV and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has been studied for decades, and the evidence points toward a real but complicated connection. EBV has been identified as a risk factor in a subset of ME/CFS patients, possibly through altered immune surveillance that allows the virus to remain more active than normal.¹⁹

One specific avenue of research has focused on a protein the virus produces called dUTPase. Studies found that a significant percentage of ME/CFS patients, between roughly 31% and 53%, were producing antibodies against dUTPase proteins from multiple herpesviruses, suggesting ongoing low-level viral activity. The EBV dUTPase protein was shown to trigger neuroinflammatory processes in animal models, producing sickness behaviors that mirror the fatigue and malaise seen in ME/CFS.²⁰ This does not mean EBV causes all cases of ME/CFS, but it provides a plausible mechanism for how the virus could contribute to chronic symptoms in some people even without a dramatic reactivation event.

EBV Reactivation and Autoimmune Disease

One of the more striking developments in EBV research over the past few years has been the strengthening evidence linking the virus to autoimmune diseases, especially multiple sclerosis (MS). EBV infection now appears to be essentially a prerequisite for MS development, with recent work providing both epidemiological and mechanistic support for a causal connection.²¹

The mechanism appears to involve a case of molecular mistaken identity. A viral protein called EBNA1, which is produced during EBV latency, shares structural similarities with a human protein called anoctamin-2 (ANO2) found in brain tissue. Researchers demonstrated that immune cells trained to recognize EBNA1 can cross-react with ANO2, and when mice were immunized with either protein, they developed cross-reactive immune responses. Importantly, pre-immunization with ANO2 worsened experimental autoimmune brain inflammation. T cell clones with this cross-reactivity have been isolated directly from MS patients, and sequencing of T cell receptors revealed significant overlap between EBNA1- and ANO2-specific cells.²² In plain terms, the immune system’s ongoing effort to control EBV can, in some genetically susceptible people, inadvertently damage the nervous system.

This research matters beyond MS. If EBV’s chronic presence can trigger one autoimmune condition through this kind of immune cross-reactivity, similar mechanisms could be at work in other autoimmune diseases. It also reframes EBV reactivation as more than a question of whether you will feel sick again from a mono-like episode; even subclinical reactivation could be relevant if it keeps supplying the immune system with viral proteins that provoke autoimmune responses.

Treatment Options and Their Limits

If you are hoping for a straightforward antiviral you can take to suppress EBV reactivation, the current situation is frustrating. No antiviral drug has been approved specifically for treating EBV infections. While several antivirals can inhibit EBV replication in laboratory settings, their success in actual patients has been limited.²³ The core difficulty is that antivirals target actively replicating virus, and during latency, EBV is not replicating. It is sitting quietly inside memory B cells, and current antivirals cannot touch it there.

For immunocompromised patients who develop significant EBV reactivation, the available strategies include reducing immunosuppressive medications when possible, using nucleoside analogs like ganciclovir, and deploying EBV-specific cytotoxic T cells or the monoclonal antibody rituximab.²⁴ A clinical trial combining a drug that forces latent virus into its active phase (making it vulnerable to antivirals) with ganciclovir has been explored for EBV-related lymphomas. But for the typical otherwise healthy person whose mono symptoms seem to be flaring, the honest answer is that treatment remains supportive: rest, fluids, pain management, and time.²⁵

The Search for an EBV Vaccine

Given that EBV infects nearly everyone and is linked to cancers, autoimmune diseases, and chronic fatigue conditions, you might wonder why there is no vaccine. Researchers have been working on one for decades, targeting viral surface proteins like gp350 and latent-phase proteins. But EBV’s complex life cycle, shifting between multiple latent programs and an active replication phase, and its ability to infect several types of immune cells make designing a broadly effective vaccine genuinely difficult.²⁶

The recent wave of mRNA vaccine technology has brought renewed energy to the field. Multiple mRNA-based EBV vaccine candidates are now in development, alongside nanoparticle-based approaches, though none has yet been approved for clinical use.²⁷ If any of these candidates prove successful, they could potentially prevent both the initial infection that leads to mono and the lifelong viral persistence that makes reactivation possible in the first place. For now, though, the immune system remains the only real defense against EBV flare-ups, which brings the practical advice back to supporting it: managing stress, getting adequate sleep, and not ignoring unexplained fatigue or illness that could indicate reactivation is underway.

Asymptomatic Shedding and Transmission After Recovery

A practical concern many people have is whether they are still contagious years after their original mono infection. The answer is yes, intermittently. Because EBV periodically reactivates at low levels, most carriers shed the virus in their saliva at least some of the time. The study that detected EBV DNA in 90% of healthy adults’ throat washings underscores that viral shedding is the norm, not the exception, among people who carry the virus.³ This is actually how EBV maintains itself in the human population: not through dramatic outbreaks, but through quiet, ongoing transmission from people who have no idea they are shedding virus.

For most adults this is a moot point, since the vast majority of the population already carries EBV. But it is relevant in some situations. Parents who had mono sometimes worry about transmitting the virus to their young children. While children who encounter EBV early in life typically have very mild or completely unnoticed infections, the shedding data confirms that household transmission is essentially unavoidable over time. The same applies to romantic partners: the reason mono is sometimes called “the kissing disease” is not that a kiss during acute illness is uniquely dangerous, but that saliva-based transmission occurs continuously at low levels from anyone who carries the virus. The strong T cell response that healthy carriers maintain keeps the reactivation from becoming a problem for the carrier, but it does not prevent occasional viral shedding that could infect someone new.²⁸

1
PubMed Central. Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells
2
PubMed Central. The T-cell Response to Epstein-Barr Virus-New Tricks From an Old Dog
3
Microbes and Infection. Detection of Epstein-Barr virus in salivas and throat washings in healthy adults and children
4
Psychoneuroendocrinology. Plasma cortisol levels and reactivation of latent Epstein-Barr virus in response to examination stress
5
PubMed. Stress-related Epstein-Barr virus reactivation
6
PubMed. Interleukin-17A directly triggers Epstein-Barr virus lytic reactivation in latency I human B-cell models
7
PubMed Central. Incidence of Epstein-Barr virus reactivation is elevated in COVID-19 patients
8
PubMed Central. Review of a Large Clinical Series Reactivation of EBV and CMV in Severe COVID-19—Epiphenomena or Trigger of Hyperinflammation in Need of Treatment? A Large Case Series of Critically ill Patients
9
Expert Reviews in Molecular Medicine. Infectious mononucleosis and Epstein-Barr virus
10
PubMed. Clinical characteristics of primary and reactivated Epstein-Barr virus infection in children
11
PubMed Central. Recurrence of infectious mononucleosis in adults after remission for 3 years: A case report
12
PubMed. Immunocompromised Patients with Therapy-Refractory Chronic Skin Diseases Show Reactivation of Latent Epstein‒Barr Virus and Cytomegalovirus Infection
13
PubMed Central. Chronic Active Epstein-Barr Virus Disease
14
PubMed Central. A Lethal Manifestation of Chronic Active Epstein-Barr Virus Infection: A Case Report
15
PubMed. Chronic active Epstein-Barr virus disease in children: Clinical outcomes and prognostic risk factors from a 149-patient cohort
16
PubMed Central. Serological diagnosis of Epstein-Barr virus infection: Problems and solutions
17
PubMed. Interpretation of EBV serology for human body material donors: Is there a need for early antigen IgG and heterophile antibodies testing?
18
PubMed Central. Coinfection with EBV/CMV and other respiratory agents in children with suspected infectious mononucleosis
19
PubMed Central. Epstein-Barr Virus and the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome
20
Clinical Therapeutics. Epstein-Barr Virus dUTPase Induces Neuroinflammatory Mediators: Implications for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
21
Nature Reviews Microbiology. Epstein–Barr virus and multiple sclerosis
22
PubMed. Anoctamin-2-specific T cells link Epstein-Barr virus to multiple sclerosis
23
PubMed Central. Novel Therapeutics for Epstein⁻Barr Virus
24
PubMed. EBV Reactivation and Lymphomagenesis: More Questions than Answers
25
Biochemical Pharmacology. Treatment of Epstein-Barr Virus infection in immunocompromised patients
26
PubMed Central. Progress in Prophylactic and Therapeutic EBV Vaccine Development Based on Molecular Characteristics of EBV Target Antigens
27
PubMed Central. Recent Progress in the Vaccine Development Against Epstein-Barr Virus
28
Infection, Genetics and Evolution. T cell-mediated immunity during Epstein–Barr virus infections in children